Global opioid agonist treatment: a review of clinical practices by country.

ABSTRACT:

Aims

We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD), specifically methadone and buprenorphine, including buprenorphine-naloxone, is delivered in routine clinical practice, with a focus on factors that affect access to and delivery of these services. The aims of this review were to summarize eligibility criteria for entry to OAT, doses in routine clinical practice, access to and eligibility for unsupervised dosing and urine drug screening practices in OAT programs globally.

Methods

We completed searches of PubMed, Embase, and grey literature databases for cross-sectional or observational cohort studies of OAT using either methadone or buprenorphine. Dose data extracted from eligible studies were compared with guidelines provided by WHO.

Result

SUBMITTER: Jin H 

PROVIDER: S-EPMC7554123 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature